Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: bio-techne.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2026 | $62.00 | Outperform | RBC Capital Mkts |
| 9/3/2025 | $73.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 8/21/2025 | $70.00 | Neutral → Buy | Citigroup |
| 7/22/2025 | $65.00 | Overweight | Stephens |
| 7/9/2025 | $65.00 | Buy | TD Cowen |
| 5/30/2025 | $59.00 | Overweight | Wells Fargo |
| 4/9/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/18/2025 | $75.00 | Outperform | Evercore ISI |
| 2/19/2025 | $88.00 → $68.00 | Outperform → Neutral | Robert W. Baird |
| 5/22/2024 | $85.00 | Buy → Neutral | Citigroup |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts resumed coverage of Bio-Techne with a rating of Outperform and set a new price target of $62.00
RBC Capital Mkts upgraded Bio-Techne from Sector Perform to Outperform and set a new price target of $73.00
Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $70.00
Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00
TD Cowen initiated coverage of Bio-Techne with a rating of Buy and set a new price target of $65.00
Wells Fargo initiated coverage of Bio-Techne with a rating of Overweight and set a new price target of $59.00
KeyBanc Capital Markets downgraded Bio-Techne from Overweight to Sector Weight
Evercore ISI initiated coverage of Bio-Techne with a rating of Outperform and set a new price target of $75.00
Robert W. Baird downgraded Bio-Techne from Outperform to Neutral and set a new price target of $68.00 from $88.00 previously
Citigroup downgraded Bio-Techne from Buy to Neutral and set a new price target of $85.00
SD - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
SCHEDULE 13G - BIO-TECHNE Corp (0000842023) (Subject)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
8-K - BIO-TECHNE Corp (0000842023) (Filer)
SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
10-Q - BIO-TECHNE Corp (0000842023) (Filer)
Fastest customizable press release news feed in the world
New integrated workflow combines icIEF fractionation and mass photometryEnables direct characterization of aggregation and size within icIEF-resolved charge variantsFour-hour workflow reduces development risk and accelerates biosimilar manufacturingMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focu
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio–Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfo
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growthGrowth vectors performed well, with mid‑single‑digit growth in Proteomic Analy
MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio‑Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents
Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™.MINNEAPOLIS, April 16, 2026 /CNW/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science research tools, analytical instruments, and diagnostics, today announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the
MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time:8:00 a.m. CDTDate:May 6, 2026Dial-in:1-800-343-4136 or 1-203-518-9843 (for international callers)Conference ID:TECHQ3Webcast:https://investors.bio-techne.com/ir-calendarA recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 111
New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets. Enhancements strengthen the fully integrated COMET spatial biology ecosystem, supporting increased consumables adoption and panel expansion.MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET™ solution portfolio with the addition of the new S
MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that it will present at the following investor conferences:TD Cowen 46th Annual Health Care ConferenceMarch 3, 202611:10 AM ESTLeerink Partners Global Healthcare ConferenceMarch 10, 20268:40 AM EDTA live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigat
Ella benchtop instrument is now CE-IVD marked and available for sale in the EUEnables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on timeProvides confidence for use in clinical trials and in-house test development MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, h
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.
Live finance-specific insights
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio–Techne Corporation (NASDAQ:TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfo
MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growthGrowth vectors performed well, with mid‑single‑digit growth in Proteomic Analy
MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time:8:00 a.m. CDTDate:May 6, 2026Dial-in:1-800-343-4136 or 1-203-518-9843 (for international callers)Conference ID:TECHQ3Webcast:https://investors.bio-techne.com/ir-calendarA recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 111
MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive
MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 4, 2026 Dial-in: 1-800-579-2543 or 1-785-424-1789 (for international callers) Conference ID: TECHQ2 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and r
MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million.GAAP earnings per share (EPS) was $0.24 versus $0.21 for first quarter 2025. Delivered adjusted EPS of $0.42 compared to $0.42 for first quarter 2025.Completed the divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars. Ongoing productivity and cost containment initiatives led
MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s
MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: November 5, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ1 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-
MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million. Full year organic revenue increased 5% (5% reported) to $1.2 billion.GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago. Delivered adjusted EPS of $0.53 compared to $0.49 one year ago. Full year GAAP EPS was $0.46 versus $1.05 one year ago. Full year adjusted EPS was $1.92 versus $1.77 one year ago.Strong performance in our proteomic analytic and cell therapy growth pillars drove 4% organic growth (6% rep
This live feed shows all institutional transactions in real time.
SC 13G - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
Live Leadership Updates
MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward. Mr. Bohnen has over 20 years of experience as a senior legal advisor, including serving as Bio-Techne's Associate General Counsel since 2019. During his tenure at Bio-T
MINNEAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Bio-Teche Corporation (NASDAQ:TECH) today announced Chuck Kummeth's planned two-year transition from his position as Bio-Techne's Chief Executive Officer (CEO) effective June 30, 2024. The Company's Board of Directors has begun its search for Mr. Kummeth's replacement, evaluating both internal and external candidates to assume the CEO position upon Kummeth's retirement at the end of its fiscal 2024. It is anticipated that Mr. Kummeth will continue to serve on Bio-Techne's Board of Directors upon his retirement. Mr. Kummeth has served as Chief Executive Officer and as a member of the Company's Board of Directors since April 2013. Under Mr. Kummeth's l
MINNEAPOLIS, Dec. 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Brenda Everson as Senior Vice President, Human Resources effective January 10, 2022. Ms. Everson succeeds Struan Robertson, who will be retiring from the Company. Mr. Robertson will remain with Bio-Techne through February 11, 2022, to ensure a smooth transition. Ms. Everson has over two decades of experience as a senior human resources leader across the technology and retail industries, most recently serving as Vice President, Human Resources for Midco, a leading internet and telecommunications provider. Previously Ms. Everson spent 18 years at Apple, Inc. in positions of increa
MINNEAPOLIS, Dec. 21, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022. Mr. Geist succeeds N. David Eansor, who will be retiring from the Company. Mr. Eansor will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition. Mr. Geist has over two decades of experience as a senior life science tools leader, most recently serving as Chief Operating Officer for Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously Mr. Geist was Vice President & General Manager for two of Thermo Fisher Scientific's